An underwritten public offering of 7 million shares of common stock has been priced by Exact Sciences in hopes of obtaining gross proceeds of approximately $281.7 million. Proceeds from the offering, which includes an overallotment option for the underwriters to buy almost 1.1 million additional shares, will be used to support commercial expansion for the Cologuard colon cancer test, as well as for product development, working capital and general corporate functions.
Public offering could pull in $281.7M for Exact Sciences
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.